Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH AL 2018 | Emerging novel approaches for ALL: inotuzumab ozogamicin

Wendy Stock • 4 May 2018
ESH AL 2018
Acute Lymphoblastic Leukemia Leukemia Antibodies Inotuzumab ozogamicin

The prognosis for relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) patients is poor, with low overall survival rates; however, novel therapies are showing promising results. Here, Wendy Stock, MD, of the University of Chicago Medical Centre, Chicago, IL, discusses the use of inotuzumab ozogamicin, a humanized anti-CD22 antibody-drug conjugate (ADC) in Phase III trials in both the R/R (NCT01564784) and frontline (NCT03150693) settings. Dr Stock also discusses the results of a trial testing this agent in the frontline setting in elderly patients, as well as a planned trial investigating a chemo-free ADC and BiTE approach. This video was recorded at the 2018 European School of Haematology (ESH) Clinical Updates on Acute Leukaemias, held in Budapest, Hungary.

More from Wendy Stock

MRD testing in ALL: advice for community physicians who may not have direct access to technologies
1:38
MRD testing in ALL: advice for community physicians who may not have direct access to technologies
Wendy Stock • 28 Feb 2026
Emerging technologies being explored for MRD detection in ALL: NGS & digital droplet PCR
1:25
Emerging technologies being explored for MRD detection in ALL: NGS & digital droplet PCR
Wendy Stock • 27 Feb 2026
Defining AYA ALL: how this varies across different countries
1:12
Defining AYA ALL: how this varies across different countries
Wendy Stock • 27 Feb 2026
Current limitations of MRD detection in ALL & the value of NGS techniques
1:54
Current limitations of MRD detection in ALL & the value of NGS techniques
Wendy Stock • 27 Feb 2026

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals